Interleukin receptor accessory protein (IL-1RAP) is another promising target on the surface of the LSCs of AML, myelodysplastic syndrome, and chronic myeloid leukemia (CML) but not on healthy HSCs, and it was shown to be effective in vitro and in vivo [64]. The gene discussed is IL1RAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.